ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
September 10 2024 - 1:09PM
ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP)
today provided an update on the status of the completion of its
previously announced acquisition of Alimera Sciences, Inc.
(“Alimera”) (Nasdaq: ALIM).
We note the Alimera press release issued today.
The Company continues to work in good faith toward closing of the
acquisition. Any delay is a result of discussions regarding closing
conditions, which the Company expects to resolve promptly.
About ANI Pharmaceuticals,
Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a
diversified biopharmaceutical company serving patients in need by
developing, manufacturing, and marketing high-quality branded and
generic prescription pharmaceutical products, including for
diseases with high unmet medical need. ANI is focused on delivering
sustainable growth by scaling up its Rare Disease business through
its lead asset Purified Cortrophin® Gel, strengthening its Generics
business with enhanced research and development capabilities,
delivering innovation in Established Brands, and leveraging its
U.S. based manufacturing footprint.
Forward-Looking Statements
This press release contains forward-looking statements. Such
risks and uncertainties include, among others, the risks and
uncertainties related to market conditions and satisfaction of
closing conditions related to the Alimera acquisition and risks
relating to ANI’s business, including those described in periodic
reports that ANI files from time to time with the SEC. ANI may not
consummate the acquisition described in this press release. Any
risks and uncertainties could materially and adversely affect ANI’s
results of operations, which would, in turn, have a significant and
adverse impact on ANI’s stock price. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and ANI specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Relations:Lisa M.
Wilson, In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Aug 2024 to Sep 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Sep 2023 to Sep 2024